Clinical and laboratory profile of patients with sickle cell anemia

Abstract

ObjectiveThis study aimed to describe and analyze clinical and laboratory characteristics of patients with sickle cell anemia treated at the Hemominas Foundation, in Divinópolis, Brazil. Furthermore, this study aimed to compare the clinical and laboratory outcomes of the group of patients treated with hydroxyurea with those patients that were not treated with hydroxyurea.MethodsClinical and laboratorial data were obtained by analyzing medical records of patients with sickle cell anemia.ResultsData from the medical records of 50 patients were analyzed. Most of the patients were female (56%), aged between 20 and 29 years old. Infections, transfusions, cholecystectomy, splenectomy and systemic arterial hypertension were the most common clinical adverse events of the patients. The most frequent cause of hospitalization was painful crisis. The majority of patients had reduced values of hemoglobin and hematocrit (8.55 ± 1.33 g/dL and 25.7 ± 4.4%, respectively) and increased fetal hemoglobin levels (12 ± 7%). None of the clinical variables was statistically significant on comparing the two groups of patients. Among hematological variables only hemoglobin and hematocrit levels were statistically different between patients treated with hydroxyurea and untreated patients (p-value = 0.005 and p-value = 0.001, respectively).ConclusionSickle cell anemia requires treatment and follow-up by a multiprofessional team. A current therapeutic option is hydroxyurea. This drug reduces complications and improves laboratorial parameters of patients. In this study, the use of the drug increased the hemoglobin and hematocrit levels of patients.

The Prevalence of Avascular Necrosis in Adults With Sickle Cell Disease in King Fahad Hospital.

“…We studied the hematological indices of all subjects, we found that the majority of SCA patients have a lower hemoglobin and hematocrit levels (7.0 -10.4 g / dl and less than 40%, respectively). These results support previous studies conducted in Nigeria and Brazil [23,24,25]. Although maintaining hemoglobin levels in SCA patients is a principle in managing SCA, it has been reported that patients 866 who tend to develop complications like frequent sever crisis and AVN have higher hemoglobin, hematocrit and RBCs levels than others [23].…”

Prevalence of Sickle Cell Among Patients Attending Immunogenetic Diagnostic Laboratory Akwanga, Nasarawa State Nigeria

“…It is also observed from this study that 80% of the patients with HbSS were either 20 years of age or less. This age range is similar to the findings of [26] in Brazil who also reported a sickle cell prevalent rate consistent with age range of 20 -29 years. Sickle Cell Disease ultimately results in multiple organ failure and pre-mature death occurring mostly in children under five years and adolescents [11].…”

Fatores de risco para mortalidade em pacientes com doença falciforme: uma revisão integrativa

“…Although gender does not present Mortality in sickle disease Pompeo CM, Cardoso AIQ, Souza MC, Ferraz MB, Ferreira Júnior MA, Ivo ML a genetic predominance in SCD, female predominance was observed in the population. 29 Likewise, the observed data regarding genotype are also in line with the worldwide literature that shows that HbSS is the most prevalent genotype in Brazil and worldwide and can reach about 70% of all cases of SCD diagnosed. 30,31 Regarding mortality, the data were also similar.…”